Leveraging collaborations and internal discoveries, we have identified seven drug candidates and developed a robust pipeline of product candidates. Currently, our pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as four preclinical candidates.